absorption - Captains Krill Oil

If your knees ache in the morning and you’ve been told omega-3s might help, you’ve probably ended up staring at two bottles in the supplement aisle: fish oil, which is cheap and everywhere, and krill oil, which costs more and promises to be the smarter molecule. The question you’re really asking is simple. For a sore joint, does the more expensive one earn its price?

I sell krill oil for a living, so you’d expect me to tell you it does. Instead I’m going to walk you through what the trials actually found, including the one I’d least like to talk about — a large, well-run 2024 study that tested krill oil for exactly this purpose and came up empty. The honest answer is that the science here is genuinely mixed, there is no clean head-to-head trial pitting krill against fish oil for joint pain, and the gap between the two forms is almost certainly smaller than the marketing on either bottle would have you believe.

Here’s the longer version, because the details are where the real answer lives.

First, the uncomfortable part: there’s no true head-to-head trial

People search “krill oil vs fish oil for joints” expecting that somewhere, someone ran the obvious experiment — same people, same joints, half on krill and half on fish oil, and measured who hurt less. As far as the published literature goes, that trial doesn’t exist. What we have instead is a scatter of separate studies: some testing krill oil against a placebo, some testing fish oil against a placebo, and a handful comparing how much omega-3 each one gets into your blood. To answer the comparison question, you have to lay those studies side by side and reason across them, which is a weaker kind of evidence than a direct contest. Anyone who tells you krill “beats” fish oil for joints is extrapolating, not quoting a result. Keep that in mind for the rest of this, including the parts where I’m doing the same thing.

What the krill oil joint trials actually found

Krill oil has been tested against placebo for knee pain three notable times, and the results don’t line up as neatly as I’d like.

The first, a small 2016 randomized trial in adults with mild knee pain, found that 2 grams a day improved pain during sleep and standing over 30 days. Encouraging, but small and short.

Then came the study krill’s defenders love to cite: a 2022 multicenter trial published in the American Journal of Clinical Nutrition00084-3/fulltext) (Stonehouse et al.), 235 adults with mild-to-moderate knee osteoarthritis, 4 grams of krill oil a day for six months. It found statistically significant improvements in WOMAC scores for stiffness, physical function, and total knee score versus a placebo oil. Notably, the people who improved the most were those who started with the highest inflammation, measured by elevated baseline CRP — a clue that omega-3s may do more for an inflamed joint than a merely worn one. This was, at the time, the largest and most rigorous krill-for-knees study on record, and it was a genuine win.

And then came the one I owe you. In 2024, a team at Monash University published a 262-person trial in JAMA — patients with clinical knee osteoarthritis who had real pain and visible inflammation (effusion-synovitis) on MRI, given 2 grams of krill oil a day for 24 weeks. The result: no improvement in knee pain over placebo. The mean difference on a 100-point pain scale was 0.3 points, with a P value of 0.94, which in plain English means the two groups were indistinguishable. The authors concluded the data “does not support” krill oil at that dose for this population.

So one large positive trial, one large negative trial, in the same disease, a couple of years apart. What separates them? Probably three things: the negative trial used a lower dose (2 grams vs. 4), it deliberately enrolled people with more advanced, visibly inflamed joints, and the placebo group happened to improve a lot on its own — which is maddeningly common in pain research. None of that lets me wave the 2024 result away. The most you can honestly say is that krill oil may help milder, inflammation-driven knee pain at a high enough dose, and that the evidence is far from settled. A newer 2025–2026 pilot study is now testing 4 grams a day in older adults with more severe chronic pain, mostly to establish whether people will stick with that dose — which tells you the researchers themselves think dose and adherence are the open questions.

What fish oil’s own joint evidence looks like

Fish oil doesn’t get a free pass here either. Its evidence for osteoarthritis is in roughly the same boat: suggestive, inconsistent, and limited by small, biased studies.

A 2023 meta-analysis in the Journal of Orthopaedic Surgery and Research pooled the omega-3 osteoarthritis trials and concluded that supplementation does help relieve pain and improve joint function — but flagged that the underlying evidence is low quality, drawn from only a handful of trials with a high risk of bias. A separate 2020 trial in Rheumatology Advances in Practice found that DHA-rich fish oil reduced osteoarthritis-specific pain in overweight, sedentary older adults over 16 weeks. And a thoughtful 2024 review in Arthritis Care & Research by Felson and colleagues looked across the essential-fatty-acid-and-osteoarthritis literature and landed on a cautious “maybe, for some people, modestly” — which is about the most honest summary anyone has offered.

One detail worth carrying forward: across this research, EPA appears to be the omega-3 with the strongest anti-inflammatory effect. That matters because EPA-to-DHA ratios differ between products, and a high-EPA fish oil concentrate may, on the inflammation front, have an edge that has nothing to do with whether the oil came from a fish or a krill.

The bioavailability argument — and why it matters less for joints than the label implies

Here’s where krill oil’s marketing does its heaviest lifting. Krill oil carries its EPA and DHA in phospholipid form, while standard fish oil carries them as triglycerides or ethyl esters. Phospholipids mix more readily into the watery contents of your gut, so they tend to absorb a bit more efficiently. A network meta-analysis published in October 2024 supports this: across dozens of studies, the phospholipid form showed superior absorption, especially at lower doses.

That’s a real advantage — but notice what it is and isn’t. “More efficiently absorbed per milligram” is not the same as “more total omega-3 in your blood.” Krill oil bottles usually contain less EPA and DHA per gram than concentrated fish oil, so the absorption edge often just offsets the lower payload. In fact, a separate dose-matched trial found no difference in the EPA and DHA your red blood cells end up with after four weeks of krill versus fish oil. For your joints specifically — which care about how much omega-3 reaches the tissue over months, not how slickly it crossed the gut wall on day one — the phospholipid story is more elegant than it is decisive. It’s a reason to consider krill, not a reason to be certain about it.

The lever that actually moves the needle: dose and consistency

Strip away the form wars and a quieter pattern emerges from all of these trials. The studies that worked tended to use real doses — 2 to 4 grams of oil daily, often delivering well over a gram of combined EPA and DHA — taken consistently for months. Omega-3s are not aspirin. They don’t switch off a sore joint in an afternoon; they slowly shift the balance of inflammatory signaling, and that takes 8 to 12 weeks of not missing days before you can fairly judge whether it’s doing anything.

This is the unglamorous truth that both industries would rather not lead with: the person who takes a cheap fish oil every single morning for three months will almost certainly do better than the person who buys a premium krill oil and remembers it twice a week. Whatever modest benefit omega-3s offer your joints, it is entirely hostage to whether you actually keep taking them. That, and not the molecular form, is where most people lose the benefit.

So which should you take?

If you’ll take either one faithfully, the honest expectation is similar — a modest improvement for some people, especially if your joint pain is inflammation-driven and your starting omega-3 intake is low, and little to nothing for others. That’s not a satisfying answer, but it’s the true one.

Where the choice genuinely tilts toward krill oil is tolerability. The most common reason people quit fish oil is the fishy reflux and aftertaste, and krill oil’s phospholipid form tends to cause far less of it. If burps are what’s stopping you from being consistent, then krill solves the only problem that actually matters — it gets you to keep taking it. Where the choice tilts toward fish oil is cost and dose: if you need a high daily gram-count of EPA and DHA and price is a constraint, a concentrated fish oil delivers more omega-3 per dollar, and consistency is easier to afford. And if your pain is significant and persistent, the most useful thing this article can tell you isn’t which oil to buy — it’s to talk to a clinician about whether omega-3s belong in your plan at all, because for advanced osteoarthritis the 2024 trial is a real cautionary note.

A note on Captains

We make a krill oil, so you’d be right to read everything above with a raised eyebrow. But the reason I’ll point you to the 2024 null result instead of burying it is the same reason our oil is mechanically extracted with no chemical solvents at any stage and ships with a full certificate of analysis for every batch: if we’re going to ask you to trust what’s in the bottle, we have to be straight about what it can and can’t do. Krill oil is a clean, well-absorbed, easy-to-tolerate way to get your omega-3s, and for the right person with the right joint, it may help. It is not a cure for an arthritic knee, and anyone selling it as one is selling you something we won’t. Honest answer, not a pitch. — captainskrilloil.com

Three Forms, One Fatty Acid

EPA and DHA — the two omega-3 fatty acids your body actually uses — are the same molecules regardless of how they’re packaged. The difference between supplements is the vehicle those molecules ride in from your gut into your bloodstream. There are three common ones:

Ethyl esters (EE). The cheapest form. Created during the concentration process when omega-3s are chemically bonded to ethanol. This is what most bargain-shelf fish oil capsules contain. Your body has to strip the ethanol bond before it can absorb the EPA and DHA, which makes it the slowest and least efficient form. Ethyl esters also depend heavily on dietary fat for absorption — take them on an empty stomach and you lose a significant chunk of the dose.

Triglycerides (TG). The natural form found in fish tissue. Three fatty acid chains attached to a glycerol backbone. Your pancreatic lipase knows exactly what to do with this structure — it’s the same form you’d get from eating salmon. Better absorbed than ethyl esters, and the form used in most mid-to-premium fish oil products. Re-esterified triglycerides (rTG) are a concentrated version that tests at the top of the bioavailability charts alongside phospholipids.

Phospholipids (PL). The form found in krill. Instead of three fatty acid chains on a glycerol backbone, you get two fatty acid chains plus a phosphate head group — the same architecture your own cell membranes use. This structural similarity means phospholipid omega-3s integrate into micelles more readily in the gut and don’t require the same enzymatic processing as triglycerides or ethyl esters before absorption (Pham et al., 2024). About 60–70% of the omega-3s in krill oil are bound to phospholipids, with phosphatidylcholine being the dominant carrier.

What the Absorption Studies Actually Show

The bioavailability question has been studied enough times that a rough hierarchy has emerged. The 2025 consensus, drawn from studies published between 2018 and 2024, ranks the forms: rTG ≈ PL > TG > EE. Re-esterified triglycerides and phospholipids sit at the top, natural triglycerides in the middle, ethyl esters at the bottom (MVS Pharma, 2024 review).

A 2024 network meta-analysis — the most comprehensive comparison to date — pooled data across multiple dosage levels and molecular forms. At doses below 2,000 mg (which covers most consumer supplements), krill oil’s phospholipid form showed enhanced area-under-the-curve plasma levels compared to standard fish oil triglycerides (Clinical Nutrition ESPEN, 2024). The advantage was most pronounced at low doses — exactly the range where most people are actually supplementing.

A 2023 randomized, double-blind crossover study compared phospholipid-enhanced fish oil against krill oil directly. The absorption totals were similar, but the profiles differed: the phospholipid forms showed higher, earlier plasma peaks, meaning the omega-3s reached the bloodstream faster (PubMed, 2023).

I want to be careful here. “Better absorbed” is not the same thing as “better for your health.” A 2024 meta-analysis of 64 randomized controlled trials found no significant difference in triglyceride, LDL, HDL, or total cholesterol levels between krill oil and fish oil. The absorption advantage doesn’t always translate into measurably different clinical outcomes — at least not in the endpoints that have been studied so far.

That said, one newer trial pushes back on that conclusion slightly. A 2026 pilot RCT in BMC Complementary Medicine and Therapies randomized 47 patients with hypertriglyceridemia to phospholipid-bound omega-3s (825 mg/day EPA+DHA) or standard omega-3s (903 mg/day EPA+DHA) for 12 weeks. The phospholipid group’s mean triglycerides dropped 9.1 mg/dL; the standard group’s rose 15.2 mg/dL. More notably, 36.4% of the phospholipid group hit the ≤150 mg/dL target versus 13.6% in the standard group (PMC, 2026). It’s a small, pilot study — not proof. But the direction is interesting, and it’s the first head-to-head clinical outcomes trial between the two forms.

The Omega-3 Index Difference

The omega-3 index — the percentage of EPA and DHA in your red blood cell membranes — is arguably a better measure of whether the omega-3s you’re swallowing are actually making it into your cells. The target is 8% or higher. Most Americans sit at 4–5%.

A controlled crossover trial gave 24 healthy volunteers either krill oil or fish oil, each providing 600 mg of omega-3s, for four weeks with washout periods between. Krill oil raised the omega-3 index more than fish oil at the same dose. EPA levels in red blood cells were significantly higher after the krill oil phase. DHA rose compared to control in the krill oil group but didn’t reach significance in the fish oil group (Ramprasath et al., Lipids in Health and Disease, 2013).

An earlier comparative bioavailability study found the same pattern: the highest incorporation of EPA and DHA into plasma phospholipids came from krill oil, followed by re-esterified triglyceride fish oil, then ethyl ester fish oil (Schuchardt et al., 2011).

What this means practically: milligram for milligram, more of the EPA and DHA from phospholipid-bound omega-3s ends up in your cell membranes, where it does its work. A smaller dose of the phospholipid form can move the needle on your omega-3 index as much as a larger dose of triglyceride fish oil.

Why the Form Affects Whether You Actually Take It

This is the part that matters more than any bioavailability chart.

“Fish burps” are the single most cited reason people stop taking fish oil. The mechanism is straightforward: triglyceride oil doesn’t mix with water. It floats on top of your stomach contents. If you get any reflux — and a lot of people do — what comes up tastes like fish. The larger the capsule, the worse the problem, and standard fish oil capsules are not small.

Phospholipids behave differently in the stomach. They’re amphiphilic — one end dissolves in water, the other in fat — which means they emulsify in stomach fluid rather than pooling on top of it. This is the same reason egg yolks emulsify a vinaigrette: the phospholipids in the yolk bridge the oil and water. In practice, this means krill oil supplements are far less likely to repeat on you, and the capsules are typically smaller because the dose doesn’t need to be as large to deliver the same amount of usable EPA and DHA.

For most healthy adults, this is a comfort-of-use difference. Annoying but manageable. But for people with GI sensitivity, people on GLP-1 medications (where nausea and reflux are already daily features), or anyone who has quietly stopped taking fish oil because the experience was unpleasant — this is the difference between a supplement they take and a supplement that sits in the cabinet.

Consistency beats potency. A 500 mg dose you take every day will always outperform a 2,000 mg dose you take when you remember, which will always outperform a 3,000 mg dose you bought once, tried twice, and abandoned.

Astaxanthin: The Bonus You Didn’t Ask About

Krill oil is red. That color comes from astaxanthin, a carotenoid antioxidant that krill accumulate from the microalgae they eat. It’s not added during manufacturing — it’s part of the animal.

Astaxanthin does two practical things in the context of an omega-3 supplement. First, it protects the omega-3 fatty acids themselves from oxidation. Omega-3s are polyunsaturated, which means they have multiple double bonds in their carbon chain — and each one is a site where oxygen can attack the molecule and turn it rancid. Fish oil manufacturers add synthetic antioxidants (usually tocopherols) to slow this down. Krill oil comes with its own antioxidant already built in (Marine Drugs, 2021).

Second, astaxanthin has its own modest evidence base as an anti-inflammatory and antioxidant in human tissue — separate from whatever it does for the oil in the capsule. I wouldn’t buy a supplement for astaxanthin alone, but getting it included in your omega-3 isn’t nothing.

Where the Form Doesn’t Matter

If you eat fatty fish twice a week — real fatty fish, not tilapia — you probably don’t need to think about any of this. Salmon, sardines, mackerel, and anchovies deliver omega-3s in their natural triglyceride form, packaged with the fats and proteins your digestive system evolved to handle. No supplement form will beat that.

If you’re taking a high-quality re-esterified triglyceride fish oil and tolerating it well, your absorption is already near the top of the hierarchy. Switching to krill oil would give you a slightly different absorption profile and smaller capsules, but the practical difference in outcomes is unlikely to be meaningful. Don’t fix what isn’t broken.

If cost is the primary constraint, a standard triglyceride fish oil taken consistently with a meal containing some fat will get the job done. It won’t absorb as efficiently as rTG or phospholipid forms, but the gap narrows when you take it with food, and the most important variable is still whether you take it at all.

Where It Does Matter

The form starts to matter when tolerability is the bottleneck — when you’ve tried fish oil and the experience was bad enough that you stopped. It matters when the dose needs to be small because appetite is low, stomach space is limited, or nausea is already part of the picture. It matters when you want to move the omega-3 index with the minimum effective dose rather than swallowing four large capsules a day.

It matters, in other words, for exactly the people who are most likely to be under-supplemented: the ones who tried and quit.

Captains Krill Oil™ is one option in this space. We make an honest, small-batch phospholipid omega-3 product — always have. But the more important thing than which brand you pick is that you’re getting EPA and DHA from somewhere, in a form you’ll actually take, at a dose that moves your number. The molecule is the point. The vehicle is just how it gets there.

If you want to know where you stand, the omega-3 index test costs about $50 and gives you a real number. Target is 8% or higher. That number matters more than which bottle is on your shelf.

Tag: absorption

Krill Oil vs. Fish Oil for Joint Pain: What the Studies Actually Show